Description
Introduction
Avascular necrosis is the death of the bone tissue due to a lack of blood supply and is also known as osteonecrosis. Avascular necrosis can lead to tiny breaks in the bone, and this eventually leads to the collapsing of bones. This condition is most common in individuals between the ages of 30 and 50. In recent years, the occurrences of avascular necrosis have increased as a result of which the demand for therapeutic surgeries has also increased. This leads to an increase in market growth. The prevalence of avascular necrosis has increased in recent years. The condition also accompanies diseases such as cancer which would have a similar medical condition. According to a study published in the Journal of the Korean Association of Oral and Maxillofacial Surgeons in 2016, the prevalence of bisphosphonate-related necrosis was estimated to be about 2.6% in 2013. The growing cases of bisphosphonate-related necrosis have spurred the growth of the market.
The global avascular necrosis market is expected to reach a market value of USD 1087.1 million by 2024 from USD 699.6 million in 2017 and is expected to register a CAGR of 6.58% during the forecast period from 2018 to 2024. In 2016, the Americas held the highest share of the market at 36.4%, followed by Europe and Asia-Pacific with shares of 26.7% and 24.9%, respectively. The increasing burden of bone disorder in different parts of the world is expected to increase the growth of the market during the forecast period.
The global avascular necrosis market is segmented into type, site, diagnosis, treatment, end-user, and region.
The global avascular necrosis market, by type, is segmented into non-trauma related avascular necrosis and trauma-related avascular necrosis.
The global avascular necrosis market, by site, is segmented into hip bone, knee, shoulders, and others.
The global avascular necrosis market, by diagnosis, is segmented into biopsy and imaging.
The global avascular necrosis market, by treatment, is segmented into electrical stimulation, gene therapy, surgery, and medication.
By distribution channel, the global avascular necrosis market is segmented into hospitals and clinics, diagnostic centers, and ambulatory surgical centers.
The global avascular necrosis market is expected to have a value of USD 1087.1 million by 2024 from USD 699.6 million in 2017 and is expected to register a CAGR of 6.58 % during the forecast period from 2018 to 2024.
Key Players
Bayer Healthcare AG, Sanofi, Boehringer Ingelheim GmbH, Pfizer Inc, Merck KGaA, Stryker Corporation, Medtronic PLC, Aurobindo Pharma, Integra Life Sciences Corporation, Zimmer Biomet Holdings, Wright Medical Group N.V., Grifols SA, Smith & Nephew, and Ethicon Inc.
Study objectives
To provide a detailed analysis of the market structure along with a forecast of various segments and sub-segments of the global avascular necrosis market
? To provide insights into factors influencing and affecting the market growth
? To provide historical and forecast revenue of market segments and sub-segments with respect to countries
? To provide strategic profiling of key players in the market and comprehensively analyzing their market share, core competencies, and drawing a competitive landscape for the market
? To provide economic factors that influence the global avascular necrosis market
? To provide a detailed analysis of the value chain and supply chain of the global avascular necrosis market
Target Audience
? Avascular Necrosis Manufacturers
? Supplier and Distributors
? Pharmaceutical Companies
? Research and Development (R&D) Companies
? Market Research and Consulting Service Providers
? Potential Investors
? Raw Material Suppliers
Key Findings
? The global avascular necrosis market is expected to reach USD 1087.1 million by 2023 at a CAGR of 6.58 % from 2018 to 2024
? On the basis of type, avascular necrosis accounted for the largest market share at a CAGR of 6.20% in 2017
? The Americas is expected to hold the largest share of the global avascular necrosis market at a CAGR of 6.32% by 2024.
? Asia-Pacific is the fastest growing market, which is expected to register a CAGR of 6.90% by 2024
Regional Analysis
? Americas
o North America
? US
? Canada
o South America
? Europe
o Germany
o France
o UK
o Italy
o Spain
o Rest of Europe
? Asia-Pacific
o Japan
o China
o India
o Australia
o Republic of Korea
o Rest of Asia-Pacific
? Middle East & Africa
o Middle East
o Africa
Table of Contents
Table of Contents:
1 Executive Summary
2 Market Introduction
2.1 Scope of Study
2.2 Research Objective
2.3 List of Assumptions
2.4 Market Structure
3 Research Methodology
3.1 Research Process
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
3.5 Forecast Model
4 Market Dynamics
4.1 Introduction
4.2 Drivers
4.2.1 Increasing awareness along with the high prevalence of the avascular necrosis disease
4.2.2 Rising preference of surgeries to cure osteonecrosis
4.2.3 Rising preference of bone grafting surgical procedures with the less pain substitute procedures
4.2.4 Consolidation of large healthcare providers in the U.S.
4.2.5 Technological advancements in the development of surgical implants
4.3 Restraints
4.3.1 The high cost of surgical procedures and related side effects
4.3.2 Worsening regulatory landscape and growing cost of noncompliance in developed countries
4.4 Opportunities
4.4.1 Growing demand for non-invasive treatments for faster recovery
4.5 Technology Trends & Assessment
4.5.1 Acceptance of synthetic bone-graft over natural ones
4.5.2 Nanotechnology
4.5.3 Rising demand for incorporating recombinant DNA technology in surgical implants
4.5.4 Development of titanium-foam implant for bone grafting
4.5.5 Customized Degradable Implants
5 Market Factor Analysis
5.1 Porter’s Five Forces Model
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.2.1 Research & Development
5.2.2 Manufacturing
5.2.3 Distribution
5.2.4 Marketing & Sales
5.2.5 Post-Sales Monitoring
5.3 Epidemiology of Avascular Necrosis
6 Global Avascular Necrosis Market, by Type
6.1 Introduction
6.2 Non-trauma Related Avascular Necrosis
6.2.1 Age Group
6.2.1.1 Third Decade
6.2.1.2 Fifth Decade
6.2.2 Causes
6.2.2.1 Caisson disease
6.2.2.2 Sickle cell anaemia
6.2.2.3 Steroid Abuse
6.2.2.4 Alcohol Abuse
6.3 Trauma-Related Avascular Necrosis
7 Global Avascular Necrosis Market, by Site
7.1 Introduction
7.2 Hip Bone
7.3 Knee
7.4 Shoulder
8 Global Avascular Necrosis Market, by Diagnosis
8.1 Introduction
8.2 Imaging
8.2.1 X-Ray
8.2.2 CT Scan
8.2.3 MRI
8.2.4 PET
8.3 Biopsy
9 Global Avascular Necrosis Market, by Treatment
9.1 Introduction
9.2 Medication
9.2.1 Medication by NSAIDs (Non-Steroidal Anti-inflammatory Drugs)
9.2.2 Medication by Bisphosphonates
9.2.3 Medication by Blood Thinners
9.3 Electrical Stimulation
9.4 Gene Therapy
9.5 Surgery
9.5.1 Core Decompression
9.5.2 Osteotomy
9.5.3 Bone Graft
9.5.4 Arthoplasty
10 Global Avascular Necrosis Market, by End-User
10.1 Introduction
10.2 Hospitals & Clinics
10.3 Diagnostic Centers
10.4 Ambulatory Surgical Centers
11 Global Avascular Necrosis Market, by Region
11.1 Introduction
11.2 Americas
11.2.1 North America
11.2.1.1 U.S.
11.2.1.2 Canada
11.2.2 South America
11.3 Europe
11.3.1 Western Europe
11.3.1.1 Germany
11.3.1.2 France
11.3.1.3 UK
11.3.1.4 Italy
11.3.1.5 Spain
11.3.1.6 Rest of Western Europe
11.3.2 Eastern Europe
11.4 Asia Pacific
11.4.1 Japan
11.4.2 China
11.4.3 India
11.4.4 Australia
11.4.5 Republic of Korea
11.4.6 Rest of Asia Pacific
11.5 The Middle East & Africa
11.5.1.1 The Middle East
11.5.1.2 Africa
12 Competitive Landscape
12.1 Introduction
12.2 Company Market Share Analysis
12.2.1 Introduction
12.3 Key Developments
13 Company Profiles
13.1 Sanofi
13.1.1 Company Overview
13.1.2 Financial Overview
13.1.3 Products Offering
13.1.4 Key Developments
13.1.5 SWOT Analysis
13.1.6 Key Strategy
13.2 Bayer Healthcare AG
13.2.1 Company Overview
13.2.2 Financial Overview
13.2.3 Products Offering
13.2.4 Key Developments
13.2.5 SWOT Analysis
13.2.6 Key Strategy
13.3 Boehringer Ingelheim GmbH
13.3.1 Company Overview
13.3.2 Financial Overview
13.3.3 Products Offering
13.3.4 Key Developments
13.3.5 SWOT Analysis
13.3.6 Key Strategy
13.4 Pfizer Inc.
13.4.1 Company Overview
13.4.2 Financial Overview
13.4.3 Products Offering
13.4.4 Key Developments
13.4.5 SWOT Analysis
13.4.6 Key Strategy
13.5 Merck KGaA
13.5.1 Company Overview
13.5.2 Financial Overview
13.5.3 Products Offering
13.5.4 Key Developments
13.5.5 SWOT Analysis
13.5.6 Key Strategy
13.6 Stryker Corporation
13.6.1 Company Overview
13.6.2 Financial Overview
13.6.3 Products Offering
13.6.4 Key Developments
13.6.5 SWOT Analysis
13.6.6 Key Strategy
13.7 Medtronic PLC
13.7.1 Company Overview
13.7.2 Financial Overview
13.7.3 Products Offering
13.7.4 Key Developments
13.7.5 SWOT Analysis
13.7.6 Key Strategy
13.8 Aurobindo Pharma
13.8.1 Company Overview
13.8.2 Financial Overview
13.8.3 Products Offering
13.8.4 Key Developments
13.8.5 SWOT Analysis
13.8.6 Key Strategy
13.9 Integra LifeSciences Corporation
13.9.1 Company Overview
13.9.2 Financial Overview
13.9.3 Products Offering
13.9.4 Key Developments
13.9.5 SWOT Analysis
13.9.6 Key Strategy
13.1 Zimmer Biomet Holdings
13.10.1 Company Overview
13.10.2 Financial Overview
13.10.3 Products Offering
13.10.4 Key Developments
13.10.5 SWOT Analysis
13.10.6 Key Strategy
13.11 Wright Medical Group N.V.
13.11.1 Company Overview
13.11.2 Financial Overview
13.11.3 Products Offering
13.11.4 Key Developments
13.11.5 SWOT Analysis
13.11.6 Key Strategy
13.12 Grifols SA
13.12.1 Company Overview
13.12.2 Financial Overview
13.12.3 Products Offering
13.12.4 Key Developments
13.12.5 SWOT Analysis
13.12.6 Key Strategy
13.13 Smith & Nephew
13.13.1 Company Overview
13.13.2 Financial Overview
13.13.3 Products Offering
13.13.4 Key Developments
13.13.5 SWOT Analysis
13.13.6 Key Strategy
13.14 Ethicon Inc.
13.14.1 Company Overview
13.14.2 Financial Overview
13.14.3 Products Offering
13.14.4 Key Developments
13.14.5 SWOT Analysis
13.14.6 Key Strategy
14 Conclusion
14.1 Key Findings
14.1.1 CEO’s Viewpoint
14.1.2 Unmet Needs
14.1.3 Key Companies to Watch
14.1.4 Prediction
15 Appendix
15.1 Discussion Blue Print
